Fluorometholone

證據等級: L5

預測適應症: 10 個

Fluorometholone: From Ocular Inflammation to Post-Bacterial Disorder

One-Sentence Summary

Fluorometholone is a synthetic fluorinated corticosteroid formulated as a topical ophthalmic preparation, established in clinical practice for managing post-operative and allergic inflammatory conditions of the ocular surface. The TxGNN model predicts it may be effective for Post-Bacterial Disorder — specifically, inflammation sequelae following bacterial ocular infections such as trachoma and bacterial corneal ulcers — with 2 clinical trials currently supporting this direction. Current evidence is sufficient to justify a cautious forward position with structured guardrails, pending formal Phase 2 results.

Quick Overview

Item	Content
Original Indication	Ocular inflammatory conditions (post-operative inflammation, allergic conjunctivitis)
Predicted New Indication	Post-Bacterial Disorder
TxGNN Prediction Score	99.91%
Evidence Level	L3
Singapore Market Status	Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on known pharmacological information, Fluorometholone is a synthetic fluorinated glucocorticoid with established topical ophthalmic use. Its efficacy in suppressing ocular surface inflammation is well-documented, and it carries a key safety distinction compared to other ophthalmic corticosteroids: a significantly lower propensity to elevate intraocular pressure (IOP). This property makes it a preferred anti-inflammatory agent when prolonged topical steroid exposure is anticipated — for example, during post-operative recovery or in the management of chronic ocular surface disease.

Bacterial infections of the eye — most notably trachoma (Chlamydia trachomatis) and bacterial corneal ulcers — trigger destructive post-infectious inflammatory cascades that persist and cause structural damage well after the pathogen has been cleared. Corneal scarring, lid deformity (trichiasis, entropion), and permanent vision loss can all result from this unresolved inflammation, not from the infection itself. Suppressing this late-phase inflammatory response is therefore a legitimate and mechanistically coherent therapeutic target, and Fluorometholone's glucocorticoid activity directly addresses this pathway.

The plausibility of this prediction is further strengthened by the existence of two registered clinical trials that have independently validated this research question. NCT01949454, already completed in 154 patients, tested perioperative Fluorometholone to reduce recurrent trichiasis after trachoma surgery by interrupting post-operative scarring. NCT07308938, an upcoming Phase 2 trial of 174 patients, directly tests Fluorometholone as adjunctive therapy in bacterial corneal ulcers. The scientific community has therefore already converged on this therapeutic hypothesis — TxGNN's prediction aligns with an active research agenda.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01949454	N/A	Completed	154	Perioperative topical Fluorometholone as adjunct to lid-rotation surgery for trachomatous trichiasis/entropion; rationale that interrupting post-operative inflammation reduces scar formation and recurrent trichiasis. Completed in 2016 — efficacy and safety data available.
NCT07308938	Phase 2	Not Yet Recruiting	174	Directly tests adjunctive topical Fluorometholone versus standard antibiotic-alone for bacterial corneal ulcers; primary endpoint is best-corrected visual acuity (BCVA) at 3 months. Expected completion 2030. The trial's registration itself validates the scientific rationale.

Singapore Market Information

Fluorometholone is currently not registered in Singapore. No product licenses or authorisation records were found.

Safety Considerations

Package insert warnings, contraindications, and drug interaction data are not available in this Evidence Pack. The following general considerations apply based on drug class knowledge:

Class-level IOP risk: As a corticosteroid, Fluorometholone carries a risk of steroid-induced intraocular pressure elevation with prolonged use, though this risk is lower than with prednisolone acetate or dexamethasone.
Infection masking: Topical corticosteroids may mask signs of active infection; use must follow confirmation that the bacterial phase has been adequately controlled.
Glaucomatocyclitic considerations: In patients with a known steroid-responder phenotype or pre-existing glaucoma, even "low-risk" agents require IOP monitoring.

Please refer to the originator package insert for full safety information before clinical use.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Two clinical trials — one completed and one registered Phase 2 — have independently operationalised Fluorometholone in post-bacterial ocular inflammation, directly validating the mechanistic hypothesis underlying TxGNN's prediction. The absence of Singapore registration is a regulatory gap, not an evidence gap.

To proceed, the following is needed:

MOA data confirmation: Retrieve Fluorometholone's full pharmacology record from DrugBank (DB00324) to formally document its glucocorticoid mechanism for regulatory submission.
Results from NCT01949454: Extract and review the completed trachoma surgery trial's published outcome data to establish L2 evidence.
Phase 2 monitoring: Track NCT07308938 (expected completion 2030) as the pivotal trial that could elevate evidence to L2.
Singapore regulatory pathway: Evaluate HSA registration requirements; consider whether the existing global approvals (e.g., US FDA, EMA) support an abridged registration application.
Safety data package: Obtain the full TFDA or FDA package insert warnings, contraindications, and pharmacokinetic data to complete the safety dossier.
IOP monitoring protocol: Define a structured intraocular pressure monitoring plan for any prospective use, given class-level steroid response risk.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.